Table 3.

Characteristics of patients who did and did not benefit from ICIs

	Benefit N = 9	No benefit N = 49
Median age, years	65 (46–72)	69 (37–87)
Sex (male/female)	7/2	24/25	p = 0.15
PS (0–1/2–4)	9/0	41/8	p = 0.33
Smoking history (yes/no)	6/3	23/26	p = 0.48
Histology (ad/sq)	8/1	46/3	p = 1.00
EGFR mutation type (common/uncommon)	8/1	44/5	p = 0.30
Median PFS to prior EGFR TKI, months	5.3 (0.5–8.8)	12.1 (8.3–14.2)	p < 0.001

PS performance status, advanced incurable stage III/IV, rec postoperative recurrence, sq squamous carcinoma, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, common EGFR exon 19 deletion and exon 21 L858R, uncommon EGFR mutations other than common ones